<?xml version="1.0" encoding="UTF-8"?>
<p id="p0265">Development of cell culture systems producing HCV pseudoparticles (HCVpp) and infectious HCV particles (HCVcc) has shed light on HCV interactions and enabled discovery of antiviral drugs and vaccines (
 <xref rid="bb0355" ref-type="bibr">Colpitts et al., 2016</xref>). HCVpp consist of HCV E1 and E2 glycoproteins enveloping a retroviral particle that packages 
 <italic>GFP</italic> mRNA during assembly (
 <xref rid="bb0090" ref-type="bibr">Bartosch et al., 2003</xref>). The entry efficiency of HCVpp can be quantified by FACS analysis as the number of GFP-positive cells. Use of this screening system led to discovery of a triazine derivative that blocks the entry of HCV (
 <xref rid="bb0080" ref-type="bibr">Baldick et al., 2010</xref>).
</p>
